Xeris Pharmaceuticals Inc (XERS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Sales | 83,127 | 85,807 | 74,380 | 71,539 | 60,119 |
| Cost of Goods | 10,574 | 10,947 | 10,996 | 11,898 | 8,728 |
| Gross Profit | 72,553 | 74,860 | 63,384 | 59,641 | 51,391 |
| Operating Expenses | 65,211 | 59,034 | 57,649 | 56,057 | 55,209 |
| Operating Income | 7,916 | 16,773 | 6,731 | 4,482 | -3,090 |
| Interest Expense | 6,884 | 7,153 | 7,268 | 7,358 | 7,305 |
| Other Income | 1,202 | 1,461 | 1,158 | 948 | 1,175 |
| Pre-tax Income | 2,234 | 11,081 | 621 | -1,928 | -9,220 |
| Net Income Continuous | 2,234 | 11,081 | 621 | -1,928 | -9,220 |
| Net Income | $2,234 | $11,081 | $621 | $-1,928 | $-9,220 |
| EPS Basic Total Ops | 0.01 | 0.07 | 0.00 | -0.01 | -0.06 |
| EPS Basic Continuous Ops | 0.01 | 0.07 | 0.00 | -0.01 | -0.06 |
| EPS Diluted Total Ops | 0.01 | 0.07 | 0.00 | -0.01 | -0.06 |
| EPS Diluted Continuous Ops | 0.01 | 0.07 | 0.00 | -0.01 | -0.06 |
| EPS Diluted Before Non-Recurring Items | 0.01 | 0.06 | 0.00 | -0.01 | -0.06 |
| EBITDA(a) | $12,015 | $20,836 | $10,763 | $8,466 | $897 |